Ceralasertib plus durvalumab in Ras mutant and Ras wild type advanced non-small cell lung cancer: Two cohorts of the phase II platform National Lung Matrix Trial.

Authors

Gary Middleton, Richard Buchanan, Joshua Savage, Joe De La Mata Chicharro, Manita Mehmi, Rosanna J Wilkins, Richard D W Kelly, Claire Wilson, Aditi Kanhere, Helen L Robbins, Luke Ames, Alastair Greystoke, Adam Dangoor, Judith Cave, Paul Shaw, Nicola Steele, Katy Clarke, Pooja Bhatnagar, Mary O'Brien, Sanjay Popat, Martin D Forster, James Spicer, Nicholas Coupe, Sarah Danson, David Gilligan, Dakshinamoorthy Muthukumar, Gillian Price, Yvonne Summers, Elizabeth Toy, Timothy Yap, Charles Swanton, Andrew Beggs, Heather Long, Eva Petermann, Lucinda Billingham

Published in

Clinical cancer research : an official journal of the American Association for Cancer Research. Sep 09, 2026. Epub Sep 09, 2026.

Abstract

Pre-clinical data suggests that ceralasertib, a potent ATR inhibitor, might reverse resistance to anti-PD-(L)1 in KRAS mutant lung adenocarcinoma (LUAD). Activity of ceralasertib/durvalumab was, therefore, assessed in two prospective, parallel immune checkpoint blockade (ICB)-resistant cohorts, one harbouring KRAS mutations (J1), the other without (NAJ), within the National Lung Matrix Trial.
Oral ceralasertib was administered (240 mg twice daily on days 15-28) with durvalumab (1500 mg IV, on day 1 of every 28-day cycle) until disease progression. Co-primary outcomes were objective response (OR) and 24-week durable clinical benefit (DCB). Biological impacts of ceralasertib were assessed in a human BJ-hTERT KRASV12ER-TAM model. Immunological impact of KRAS mutation was assessed using gene-level processed LUAD TCGA PanCancer data.
Between 02-Jul-2020 and 31-Oct-2021, 43 patients were registered; 19 and 18 of whom were evaluable for outcome analysis in cohorts J1 and NAJ, respectively. Cohort target recruitment (30 participants each) was not reached due to trial closure at the pre-planned end of funding. Bayesian estimates of DCB rates (95% credible intervals) were 37.7% (19.1-59.2) for J1 and 29.3% (12.6-51.2) for NAJ. Two participants demonstrated OR, both KRAS mutant, one of whom had KEAP1/STK11 co-mutation. KRAS mutation significantly increased the proportion of cells harbouring ceralasertib-induced micronuclei. Ceralasertib blunted KRAS-mediated STAT1 downregulation.
Whilst outcome measures on ceralasertib/durvalumab in anti-PD-(L)1 resistant LUAD patients are modestly higher in KRAS mutant participants, these differences are not significant, a result likely related to the modest impact of KRAS mutation alone on the immunobiology of LUAD.

PMID:
42714874
Bibliographic data and abstract were imported from PubMed on 10 Sep 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.